ABSTRACT
ObjectiveTo evaluate the efficacy and safety of Lianhua Qingke tablets in the treatment of acute bronchitis in children with the syndrome of phlegm-heat obstructing lung. MethodA randomized， open， parallel controlled， and multi-center clinical study was conduted. Children with acute bronchitis （syndrome of phlegm-heat obstructing lung） were randomly assigned to an observation group and a control group. The control group received routine basic treatment， and the observation group was treated with Lianhua Qingke Tablets on the basis of routine basic treatment. After 7 days of treatment， the clinical efficacy， TCM efficacy， time to symptom disappearance， time to cough disappearance， and clinical safety were compared between the two groups. ResultA total of 248 children were included （124 in the observation group and 124 in the control group）. After 7 days of treatment， the total response rate in terms of clinical efficacy in the observation group was 96.8% （120/124）， which was higher than that （90.3%， 112/124） in the control group （Z=-5.034， P<0.01）. The total response rate in terms of TCM syndrome in the observation group was 97.6% （121/124）， which was higher than that （93.5%， 116/124） in the control group （χ2=-5.326， P<0.01）. The scores of physical signs and TCM symptoms in the observation group were lower than those in the control group at the time of taking medicine for 3 days and 7 days （P<0.01）. The time to symptom disappearance and the time to cough disappearance in the observation group were shorter than those in the control group （P<0.01）. Drug-related adverse reactions occurred in neither group. ConclusionLianhua Qingke tablets demonstrate a definite effect on acute bronchitis in children with the syndrome of phlegm-heat blocking lung. The tablets can significantly shorten the course of disease and relieve cough and TCM symptoms， with high safety， which is worthy of clinical application and promotion.
ABSTRACT
OBJECTIVES@#To study the efficacy and safety of Xiyanping injection through intramuscular injection for the treatment of acute bronchitis in children.@*METHODS@#A prospective study was conducted from December 2021 to October 2022, including 78 children with acute bronchitis from three hospitals using a multicenter, randomized, parallel-controlled design. The participants were divided into a test group (conventional treatment plus Xiyanping injection; n=36) and a control group (conventional treatment alone; n=37) in a 1:1 ratio. Xiyanping injection was administered at a dose of 0.3 mL/(kg·d) (total daily dose ≤8 mL), twice daily via intramuscular injection, with a treatment duration of ≤4 days and a follow-up period of 7 days. The treatment efficacy and safety were compared between the two groups.@*RESULTS@#The total effective rate on the 3rd day after treatment in the test group was significantly higher than that in the control group (P<0.05), while there was no significant difference in the total effective rate on the 5th day between the two groups (P>0.05). The rates of fever relief, cough relief, and lung rale relief in the test group on the 3rd day after treatment were higher than those in the control group (P<0.05). The cough relief rate on the 5th day after treatment in the test group was higher than that in the control group (P<0.05), while there was no significant difference in the fever relief rate and lung rale relief rate between the two groups (P>0.05). The cough relief time, daily cough relief time, and nocturnal cough relief time in the test group were significantly shorter than those in the control group (P<0.05), while there were no significant differences in the fever duration and lung rale relief time between the two groups (P>0.05). There was no significant difference in the incidence of adverse events between the two groups (P>0.05).@*CONCLUSIONS@#The overall efficacy of combined routine treatment with intramuscular injection of Xiyanping injection in the treatment of acute bronchitis in children is superior to that of routine treatment alone, without an increase in the incidence of adverse reactions.
Subject(s)
Humans , Child , Injections, Intramuscular , Cough/drug therapy , Prospective Studies , Respiratory Sounds , Bronchitis/drug therapy , Treatment OutcomeABSTRACT
Background: Acute bronchiolitis is the most common lower respiratory tract infection in young infants and young children. The respiratory syncytial virus is the commonest cause of bronchiolitis. Recently the role of nebulized 3% saline has come into focus. Nebulized adrenaline has also been suggested as another treatment option, its primary role being the reduction of mucosal edema, which is an important part of the disease pathology in bronchiolitis. Objective: To see the effects of nebulized adrenaline in comparison to nebulized 3% hypertonic saline in the treatment of acute bronchiolitis. Material & Methods:This was a randomized controlled trial, carried out in the Department of Pediatrics, Bangladesh Shishu Hospital and Institute from October 2017 to March 2020. A total of 90 children from 1 month to 2 years of age of either sex who were diagnosed and admitted with acute bronchiolitis were enrolled. After enrollment, they were randomly assigned to either 3% nebulized hypertonic saline (group A=45) or to the nebulized adrenaline-1:1000 group (group B=45). Monitoring was done by respiratory distress assessment instrument (RDAI) score at 12 hours interval for 1st 24 hours and then 24 hourly till the patient was ready for discharge. The efficacy was determined by assessing clinical severity score/RDAI score and length of hospital stay. Data were analyzed using SPSS version-23.Results:The mean age was found 6.34±3.89 months in group A and 6.06±3.55 months in group B. The majority of patients were males in both groups. All patients had a cough, breathing difficulty, Ronchi, and chest indrawing in both groups. Changes in heart rate were 5.68±6.61/min in group A and 2.86±5.87/min in group B, which was significantly decreasing in group A than in group B. Mean clinical severity scores at 12 hours and at 24 hours were statistically significant (p<0.05). However, mean clinical severity scores at baseline, at 48 hours, at 72 hours, and at 96 hours were not statistically significant. The mean duration of oxygen therapy was found 15.00±5.36 hours in group A and 24.63±11.64 hours in group B. Which indicates that the duration of oxygen therapy was significantly higher in group B than in group A. Majority of the patients of group A and group B were discharged within 72 hours 39(86.7%) and 28(62.2%) respectively, which was statistically significant.Conclusions:Nebulization with 3% hypertonic saline significantly reduced clinical severity score and length of hospital stay in case of acute bronchiolitis in comparison to nebulized adrenaline.
ABSTRACT
Introducción: La bronquiolitis aguda es la infección del tracto respiratorio inferior más frecuente en el lactante. Tiene una incidencia anual del 10 por ciento en los lactantes y una tasa de ingreso de entre el 2 y el 5 por ciento con un incremento importante en los últimos años. Objetivo: Determinar la efectividad del uso de solución salina hipertónica al 3 por ciento nebulizada en pacientes con bronquiolitis aguda. Métodos: Se realizó un estudio analítico longitudinal prospectivo de tipo casos y controles. El universo estuvo constituido por 132 pacientes distribuidos en 66 casos y 66 controles. Resultados: La edad media fue de 3,6 ± 2,5 meses. Los sibilantes se hallaron en 129 pacientes, lo que representó el 97,7 por ciento. Se encontró una estadía hospitalaria media de 3,19 ± 1,41 días en los casos, mientras que en los controles se encontró una media de 4,97 ± 1,77 días, diferencia que resultó altamente significativa (p < 0,001). Conclusiones: Aunque los pacientes tratados con solución salina hipertónica al 3 por ciento necesitaron más días con oxigenoterapia, el tratamiento resultó ser efectivo al mostrar una menor estadía hospitalaria y un menor número de complicaciones en pacientes con bronquiolitis aguda(AU)
Introduction: Acute bronchiolitis is the most frequent lower respiratory tract infection in the infant. It has a yearly incidence of 10 percent in infants and an admission rate of 2 percent to 5 percent, with a significant increase in recent years. Objective: To determine the effectiveness of nebulized 3 percent hypertonic saline solution treatment in patients with acute bronchiolitis. Methods: A prospective, longitudinal and analytical study of case-control design was carried out. The universe consisted of 132 patients distributed into 66 cases and 66 controls. Results: The mean age was 3.6±2.5 months. Wheezing was found in 129 patients, accounting for 97.7 percent. A mean hospital stays of 3.19±1.41 days was found in cases, while a mean of 4.97±1.77 days was found in controls, a difference that was highly significant (P<0.001). Conclusions: Although patients treated with 3 percent hypertonic saline solution required more days with oxygen therapy, the treatment proved to be effective by showing a shorter hospital stay and a lower number of complications in patients with acute bronchiolitis(AU)
Subject(s)
Humans , Male , Female , Child, Preschool , Child , Bronchiolitis, Viral/epidemiology , Saline Solution, Hypertonic/therapeutic use , Prospective Studies , Longitudinal StudiesABSTRACT
Background: Authors define acute bronchitis as a self-limiting infection of large airways, which is characterized by cough without pneumonia. NSAIDS (Non-steroidal anti-inflammatory drugs) are prescribed in patients with Lower Respiratory Tract Infections (LRTI). In cough, fever and chest pain it is common practice to prescribe NSAIDS or antibiotics. Authors have conducted assessment of effect of medications in the resolution of cough of patients with uncomplicated acute bronchitis.Methods: It was a single blinded randomized clinical trial conducted in patients admitted to pulmonary medicine department of government medical college Shivpuri. Patients were from age group 18 to 70 years presenting with respiratory tract infection of less than one week’s duration, with cough as the predominant symptom and diagnosed with non-complicated acute bronchitis. Patients were randomized into two groups, group A and B according to medications.Results: Among 120 participants were randomized (60 to ibuprofen and 60 to antibiotic). The median number of days with frequent cough was slightly lower among patients of group A (12 days) compared with those receiving amoxicillin-clavulanic acid (14 days). No significant difference was found. Adverse effect was seen in 24 patients, which was most common in group B (15.25%) than group A (9.15%). p<0.05).Conclusions: No significant differences were observed in the number of days with cough between patients with uncomplicated acute bronchitis treated with ibuprofen or amoxicillin-clavulanic acid.
ABSTRACT
The severe respiratory insufficiency (SRI) caused by acute bronchitis whose main etiology is the respiratory syncytial virus is the main cause of under 2-year-old children hospitalization during the winter months, especially in the risk groups. Its treatment is mainly based in general measures, administration of respiratory support with standard oxygen therapy, non-invasive ventilation, invasive mechanical ventilation or the emerging high flow nasal cannula therapy, which these past few years has become an easy alternative of use, well tolerated, secure to be used in emergency rooms, basic rooms and pediatric intensive care units. The election of therapy will depend of the patient severity, the level of complexity of the healthcare center and the experience in the different treatment modalities of the health team. It is essential to carry out protocols and guidelines for the management of SRI treatment caused by acute bronchitis for emergency services, basic rooms and pediatric intensive care.
La insuficiencia respiratoria aguda (IRA) causada por bronquiolitis aguda (BA), cuya principal etiología es el virus respiratorio sincicial (VRS), es la principal causa de hospitalizaciones en menores de 2 años durante los meses de invierno, especialmente en grupos de riesgo. Su manejo se basa principalmente en medidas generales, administración de soporte respiratorio con oxigenoterapia estándar, ventilación no invasiva (VNI), ventilación mecánica invasiva (VMI) o la emergente terapia con cánula nasal de alto flujo (CNAF), que se ha transformado en los últimos años en una alternativa de fácil uso, bien tolerada, segura para ser usada en los servicios de urgencia, salas básicas y unidades de cuidados intensivos pediátricos (UCIP). La elección de la terapia a utilizar dependerá de la gravedad del paciente, del nivel de complejidad del centro asistencial y de la experiencia en las distintas modalidades de tratamiento del equipo de salud. Es fundamental realizar protocolos y guías de manejo de tratamiento de la IRA causada por BA tanto para servicios de urgencia, salas básicas como cuidados intensivos pediátricos.
Subject(s)
Humans , Infant, Newborn , Infant , Respiratory Insufficiency/etiology , Respiratory Insufficiency/therapy , Oxygen Inhalation Therapy , Respiration, Artificial/methods , Bronchiolitis, Viral/complications , Respiratory Syncytial Virus Infections/complications , CannulaABSTRACT
To evaluate the effectiveness and safety of Xiyanping Injection in the treatment of acute bronchitis in children. The research systematically retrieved four Chinese databases( namely CNKI,VIP,Wan Fang,Sino Med) and four English databases( namely EMbase,Cochrane Library,Medline,Clinical Trail.gov). The retrieval time ranged from the commencement of each database to April2019. According to pre-set inclusion criteria and exclusion criteria,randomized controlled trials( RCTs) of Xiyanping Injection in the treatment of acute bronchitis in children were screened out. The quality assessment of the included studies was performed using the " Cochrane Bias Risk Assessment" tool,and the Meta-quantitatively analysis on the included studies was performed using Rev Man 5.3 software. A total of 648 articles were retrieved,and 10 studies were finally included. Except for one multi-arm test,the total sample size was 1 260,including 630 cases in the test group and 630 cases in the control group. The overall quality of the included study was not high. The results of Meta-analysis showed that in terms of antipyretic time,Xiyanping Injection combined with routine therapy was superior to routine therapy in the shortening of fever time in children with acute bronchitis( MD =-0.94,95%CI[-1.18,-0.70],P<0.000 01); in the overall efficacy,Xiyanping Injection combined with routine therapy was superior to routine therapy( RR = 1. 34,95% CI[1.26,1.42],P<0.000 01) and Yanhuning Injection + routine therapy( RR = 1.28,95%CI[1.19,1.38],P<0.000 01); descriptive analysis showed that Xiyanping Injection was excellent in the overall efficacy in treating acute bronchitis in children. The differences between the two groups were statistically significant( P< 0.000 1). The adverse reactions included in the study were mild adverse reactions,with no impact on treatment. Based on the results of this study,Xiyanping Injection combined with routine therapy or other Western medicine had a certain effect on acute bronchitis in children,especially in improving the overall efficacy of acute bronchitis in children. No serious adverse reactions were observed. And in the time of fever,cough and cough disappearance time,lung voice loss time,Xiyanping Injection + routine therapy or Western medicine therapy was better than routine therapy or Western medicine therapy. However,the small size of included studies,the low quality of the included studies,and the existence of publication bias and the low quality of the evidence had impacts on the reliability of the conclusion. Therefore,more large-sample,multi-center,well-designed,rigorous randomized controlled trials with best case reports are required to further verify the efficacy and safety.
Subject(s)
Child , Humans , Male , Acute Disease , Bronchitis/drug therapy , Drugs, Chinese Herbal/therapeutic use , Injections , Reproducibility of ResultsABSTRACT
Objective To study the efficacy and safety of Cefpodoxime proxetil granules in the treatment of acute bronchitis in children.Methods One hundred and sixty children of the First People's Hospital of Nanning from June to December 2018 with acute bronchitis were randomly divided into cefpodoxime group and cefaclor group,with 80 cases in each group.All patients received routine treatment.On this basis,80 patients in the cefpodoxime group received oral Cefpodoxime proxetil granules 5 mg/kg (not more than 100 mg/time),twice a day;80 patients in the cefaclor group received oral Cefaclor.The granules were 10 mg/kg (not more than 250 mg/time),3 times a day,and the course of treatment was 5 days.The clinical efficacy and adverse reactions were observed.Results The cure rate and effective rate of Cefpodoxime group were 91.3％ (73/80 cases) and 95.0％ (76/80 cases),respectively,while the cure rate and effective rate of Cefaclor group were 66.3 ％ (53/80 cases) and 81.3％ (65/80 cases),respectively,and the differences between the 2 groups were statistically significant (x2 =14.94,7.23,all P ＜ 0.05).Sixty-three strains of pathogenic bacteria and 66 strains of pathogenic bacteria were obtained in Cefpodoxine group and Cefaclor group,respectively,and the detection rates of bacteria in the 2 groups were 78.75％ and 82.50％,respectively.There was no significant difference in the number of bacterial strains and strains detected in each group (x2 =0.36,P ＞ 0.05),but the total bacterial clearance rate in Cefpodoxine group was 88.9％ (56/63 cases) while the bacterial Clearance rate in Cefaclor group was 74.2％ (49/66 cases),and the difference between the 2 groups was statistically significant (x2 =4.57,P ＜ 0.05).In particular,the bacterial clearance rate in Cefpodoxine group to Streptococcus pneumoniae,Staphylococcus aureus and Klebsiella pneumoniae were significantly higher than those in Cefaclor group,while the bacterial Clearance rate of Proteus and Escherichia coli were lower than those in Cefaclor group.The incidence of adverse reactions in Cefpodoxine group and Cefaclor group were 5.0％ and 3.8％,respectively,with no significant difference (P ＞ 0.05).Conclusions The clinical effect of Cefpodoxime pro-xetil granules in treating children with acute bronchitis is more significant than that of Cefaclor.It has high safety and no serious side effect.
ABSTRACT
Objective@#To study the efficacy and safety of Cefpodoxime proxetil granules in the treatment of acute bronchitis in children.@*Methods@#One hundred and sixty children of the First People′s Hospital of Nanning from June to December 2018 with acute bronchitis were randomly divided into cefpodoxime group and cefaclor group, with 80 cases in each group.All patients received routine treatment.On this basis, 80 patients in the cefpodoxime group received oral Cefpodoxime proxetil granules 5 mg/kg (not more than 100 mg/time), twice a day; 80 patients in the cefaclor group received oral Cefaclor.The granules were 10 mg/kg (not more than 250 mg/time), 3 times a day, and the course of treatment was 5 days.The clinical efficacy and adverse reactions were observed.@*Results@#The cure rate and effective rate of Cefpodoxime group were 91.3% (73/80 cases) and 95.0% (76/80 cases), respectively, while the cure rate and effective rate of Cefaclor group were 66.3%(53/80 cases) and 81.3%(65/80 cases), respectively, and the differences between the 2 groups were statistically significant (χ2=14.94, 7.23, all P<0.05). Sixty-three strains of pathogenic bacteria and 66 strains of pathogenic bacteria were obtained in Cefpodoxine group and Cefaclor group, respectively, and the detection rates of bacteria in the 2 groups were 78.75% and 82.50%, respectively.There was no significant diffe-rence in the number of bacterial strains and strains detected in each group (χ2=0.36, P>0.05), but the total bacterial clearance rate in Cefpodoxine group was 88.9%(56/63 cases) while the bacterial Clearance rate in Cefaclor group was 74.2%(49/66 cases), and the difference between the 2 groups was statistically significant (χ2=4.57, P<0.05). In particular, the bacterial clearance rate in Cefpodoxine group to Streptococcus pneumoniae, Staphylococcus aureus and Klebsiella pneumoniae were significantly higher than those in Cefaclor group, while the bacterial Clearance rate of Proteus and Escherichia coli were lower than those in Cefaclor group.The incidence of adverse reactions in Cefpodoxine group and Cefaclor group were 5.0% and 3.8%, respectively, with no significant difference (P>0.05).@*Conclusions@#The clinical effect of Cefpodoxime pro-xetil granules in treating children with acute bronchitis is more significant than that of Cefaclor.It has high safety and no serious side effect.
ABSTRACT
Objective To study the efficacy of azithromycin in the treatment of acute bronchitis. Methods The 300 patients with acute bronchitis treated by our hospital from August 2016 to February 2017 were randomly divided into the control group and the experimental group, each with 150 patients. The control group was treated with penicillin and azithromycin was treated by the experimental group. Comparative analysis was made on the clinical indicators of the experimental group and the control group. Results After the corresponding treatment, the improvement time of cough sputum in the experimental group was (4.19 ± 0.54), and the improvement time was (4.32 ± 0.65). The improvement time of cough sputum in the control group was (6.29 ± 0.87), and the improvement of pharyngeal pain was (5.32 ± 0.76) days. However, the improvement time of cough expectorus and pharyngeal pain in the experimental group was significantly shorter than the control group, the differences were statistically significant (P＜0.05). Of the patients in the experimental group, 6 patients were not effective, 14 patients improved, 70 patients showed positive results and 60 patients recovered. In the control group, the total number of cases was 110, 15 were invalid, 25 were improved, 60 were developed and 50 were cured. However, the efficiency of the experimental group was 86.67 %, significantly higher than that in the control group (73.33 %), the differences were statistically significant (P＜0.05). The clinical recovery time of the patients in the experimental group was (5.65±1.19), which was significantly shorter than that of the control group (6.89±1.46), the differences were statistically significant (P＜0.05). Conclusion The clinical efficacy of azithromycin in the treatment of acute bronchitis is better, which can significantly improve the treatment efficiency, relieve the patient’s related symptoms, and have the significance of clinical promotion.
ABSTRACT
Objective To observe the effect on serum inflammatory factors and immune function of Shiwei Longdanhua particles in elderly patients with acute bronchitis.Methods 120 cases of elderly patients with acute bronchitis from November 2014 to October 2016 were selected and randomly divided into the observation group and the control group with 60 cases in each group, according the order of single and double number.The control group was given conventional treatment, and the observation group was given Shiwei Longdanhua particles based on the control group.Treatment for seven days, to observe the differences of serum inflammatory factors (hs-CRP, TNF-αand IL-6, IL-1) and immunologic function indexes (CD3 +, CD4 +, CD8 +, CD4 +/CD8 +and IgM, IgG, IgA) between the two groups.Results After treatment, hs-CRP, TNF-αand IL-6, IL-1 of the two groups decreased with before treatment, the difference was statistically significant (P<0.05), and all indexes of the observation group were lower than those of the control group, the difference was statistically significant ( P<0.05 ) .After treatment, CD3 +, CD4 +, CD4 +/CD8 + of the two groups increased with before treatment except CD8 +decreased, the difference was statistically significant (P<0.05), there was no significant difference between the control group and before treatment, there was significant difference between the two groups after treatment (P<0.05).After treatment, IgM, IgG and IgA of the two groups decreased with before treatment, the difference was statistically significant (P<0.05), and all indexes of the observation group were lower than those of the control group, with significant differences, the difference was statistically significant (P<0.05).Conclusion Shiwei Longdanhua particles has the effects of inhibiting inflammatory reaction and improving the immune status in the treatment of elderly patients with acute bronchitis .
ABSTRACT
Objective To study the efficacy of azithromycin in the treatment of acute bronchitis. Methods The 300 patients with acute bronchitis treated by our hospital from August 2016 to February 2017 were randomly divided into the control group and the experimental group, each with 150 patients. The control group was treated with penicillin and azithromycin was treated by the experimental group. Comparative analysis was made on the clinical indicators of the experimental group and the control group. Results After the corresponding treatment, the improvement time of cough sputum in the experimental group was (4.19 ± 0.54), and the improvement time was (4.32 ± 0.65). The improvement time of cough sputum in the control group was (6.29 ± 0.87), and the improvement of pharyngeal pain was (5.32 ± 0.76) days. However, the improvement time of cough expectorus and pharyngeal pain in the experimental group was significantly shorter than the control group, the differences were statistically significant (P＜0.05). Of the patients in the experimental group, 6 patients were not effective, 14 patients improved, 70 patients showed positive results and 60 patients recovered. In the control group, the total number of cases was 110, 15 were invalid, 25 were improved, 60 were developed and 50 were cured. However, the efficiency of the experimental group was 86.67 %, significantly higher than that in the control group (73.33 %), the differences were statistically significant (P＜0.05). The clinical recovery time of the patients in the experimental group was (5.65±1.19), which was significantly shorter than that of the control group (6.89±1.46), the differences were statistically significant (P＜0.05). Conclusion The clinical efficacy of azithromycin in the treatment of acute bronchitis is better, which can significantly improve the treatment efficiency, relieve the patient’s related symptoms, and have the significance of clinical promotion.
ABSTRACT
Objective To discuss the clinical effect of the treatment of acute bronchitis in children with the treatment of children with the treatment of children with acute bronchitis. Methods 50 patients with pediatric acute bronchitis from January 2013 to January 2016 were selected,and randomly divided into observation group and control group,25 cases in each groups.The control group with azithromycin treatment, the observation group with cloth to Ned + archie LeiSu + terbutaline therapy; To two groups of patients with detailed record and analysis of the experimental data, discussed the budesonide, azithromycin combined terbutaline clinical effect for the treatment of infantile acute bronchitis. Results After treatment,the observation group (budesonide + archie LeiSu + terbutaline) clinical curative effect is better than that of control group (azithromycin) clinical curative effect, clinical symptoms improved situation is better than that of control group, compare the difference between groups was statistically significant (P<0.05). Conclusion Children with acute bronchitis choose budesonide + archie LeiSu + terbutaline combined treatment effect significantly, can effectively improve clinical symptoms in a short time, is widely used in clinical treatment of children with acute bronchitis.
ABSTRACT
Objective:To study the efficacy and influence on serum interleukin 4 (IL-4) and interferon-γ(IFN-γ) levels of Xiy-anping injection in acute bronchitis children .Methods:Totally 74 cases of acute bronchitis children were divided into the experimental group and the control group with 37 cases in each .The control group was treated with the conventional treatment , while the experimen-tal group was given Xiyanping injection additionally .Before the treatment and in 7 days after the treatment , the level changes of IL-4 and IFN-γ, improvement time of clinical symptoms , clinical curative effect and adverse reactions of the two groups were compared .Re-sults:After 7 d treatment , two groups of children with the level of serum IL-4 levels were lower than the previous treatment , the IFN-γlevels were higher than previous treatment (P<0.05); And experimental groups with serum IL-4, IFN-γlevels were significantly better than control group (P<0.05).Experimental group’s lung sound, cough and expectoration, antifebrile time significantly were shorter than the control group(P<0.05), the clinical total effective rate was significantly higher than the control group (P<0.05). The incidence of adverse drug reactions in two groups had no statistical significance (P)0.05).Conclusion:Xiyanping injection com-bined with the conventional treatment can obviously increase serum levels of IL -4 and IFN-γin acute bronchitis children , improve the clinical symptoms of patients , and shorten the disease course with few adverse reactions and promising clinical curative effect .
ABSTRACT
OBJECTIVE:To explore the effects of inhaled budesonide on the efficacy and related indexes of patients with acute bronchitis. METHODS:102 patients with acute bronchitis were randomly divided into control group and observation group. Control group was given 100 mg/(kg·d) Cefotaxime sodium injection,adding into 150 ml 0.9% Sodium chloride injection intravenously by 2 times,as well as sedation,oxygen inhalation,rehydration,correcting acid-base balance and other conventional treatment;ob-servation group was additionally given 2 ml Inhaled budesonide suspension,twice a day. The treatment course for both groups was 7 d. Clinical efficacy,erythrocyte immune complex rosette(E-ICR),high-sensitivity C-reactive protein(hs-CRP),peak expiratory flow rate(PEF),forced vital capacity(FVC),1 second forced exhaled volume(FEV1),time of body temperature returned to nor-mal,cough disappearance time,rale disappearance time before and after treatment,and incidence of adverse reactions in 2 groups were observed. RESULTS:The total effective rate in observation group was significantly higher than control group,time of body temperature returned to normal, cough disappearance time and rale disappearance time were significantly shorter than control group,the differences were statistically significant(P0.05). After treatment,E-ICR and hs-CRP levels were significant-ly lower than before,and observation group was lower than control group,PEF,FVC and FEV1 were significantly higher than be-fore,and observation group was higher than control group,the differences were statistically significant(P<0.05). And there were no adverse reactions during treatment. CONCLUSIONS:Based on conventional treatment,inhaled budesonide has obvious efficacy in the treatment of acute bronchitis,and it can reduce E-ICR and hs-CRP,improve pulmonary functions,with good safety.
ABSTRACT
Objective: To evaluate the efficacy and safety of Qingfei Xiaoyan Pill (QXP) in the treatment of lung phlegm heat syndrome in children with acute bronchitis. Methods: Stratified random, open, parallel-group controlled, and multi-center clinical studies were applied. Totally 96 patients suffering from Xiao'er acute bronchitis were randomly divided into treatment group and the control group according to 2:1 ratio. The patients in treatment group were given QXP for application while the patients in control group were given Xiaoer Feire Kechuan Oral Liquid for application, 5 d in total. Results: The curative rates of treatment and control groups in disease efficacy were 76.92% and 50.00%, and the curative rates of both groups in traditional Chinese medicine syndrome effect were 78.85% and 60.76%. These of treatment group were better than those of control group, and there were significant differences between the two groups (P 0.05). Conclusion: QXP has a definite effect on lung phlegm heat syndrome in children with acute bronchitis with good safety and is better than Xiaoer Feire Kechuan Oral Liquid.
ABSTRACT
OBJECTIVE:To observe the efficiency and safety of budesonide,azithromycin combined with terbutaline in the treatment of infantile acute bronchitis. METHODS:150 children with acute bronchitis were randomly divided into control group(75 cases) and observation group(75 cases). All children were given electrolyte supplement,antiasthmatic,antispasmodic and other conventional treatment;based on it,control group was treated with 10 mg/kg Azithromycin injection,adding into 250 ml 5% Glu-cose injection,by intravenous infusion with time of more than 60 min,once everyday+2 mg Terbutaline sulfate spray solution,add-ing into 2 ml 0.9%sodium chloride injection,aerosal inhalation,twice a day,15 min for every times. Observation group was addi-tionally given 1.0 mg Budesonide aerosol;3 times a day,10 min for every times. The treatment course for both groups was 10 d. FEV1,MEF50,PEF before and after treatment,total effective rate and disappearance time of clinical symptoms,hospitalization time and incidence of adverse reactions were recorded. RESULTS:The total effective rate in observation group were significantly higher than control group,disappearance time of clinical symptoms and hospitalization time were significantly shorter than control group,the differences were statistically significant(P0.05). CONCLUSIONS:Based on conventional treament,budesonide,azithromycin combined with terbutaline is effective in the treatment of infantile acute bronchi-tis,and it can significantly improve lung function,with good safety.
ABSTRACT
Objective To study the relieving cough effect ofPuji-Xuanfei-Xiaodu decoction on acute bronchitis.Methods 87 patients with acute bronchitis of exterior cold and interior heat were randomly divided into two groups(44 cases in a therapy group and 43 cases in a control group).Puji-Xuanfei-Xiaodu decoction was given to the patients in the therapy group and acute bronchitis syrup was given to the control group, to observe the influence on symptoms of cough, sputum, fever and headache. The course of treatment was 7 days. Results On the reliving cough aspect, 28 cases (63.6%) showed cure effect and 13 cases (29.5%) effctive, the total effective rate was 93.2% in therapy group with 44 cases; while in control group (43 cases), 15 cases (43.9%) showed cure effect and 23 cases (53.5%) effctive, the total effective rate was 88.4%. The symptoms of cough, phlegm, fever, headache and aversion to wind were significantly decreased in two groups. In therapy group, the numbers of cure effect, remarkable effect and efficacy were 22 (50%) ,11(25%) and 8 (18.2%) cases respectively, the total effective rate was 93.19% while the numbers of cure effect, remarkable effect and efficacy were 14 (32.6%) ,8(18.6%) and 12 (27.9%) cases respectively, the total effective rate was 79.07% in control group. The total effective ratio of two groups had significant difference (P>0.05).ConclusionsPuji-Xuanfei-Xiaodu decoction is effective in relieving cough.
ABSTRACT
The role of atypical bacteria and the effect of antibiotic treatments in acute bronchitis are still not clear. This study was conducted at 22 hospitals (17 primary care clinics and 5 university hospitals) in Korea. Outpatients (aged > or = 18 yr) who had an acute illness with a new cough and sputum (< or = 30 days) were enrolled in 2013. Multiplex real-time polymerase chain reaction (RT-PCR) was used to detect five atypical bacteria. A total of 435 patients were diagnosed as having acute bronchitis (vs. probable pneumonia, n = 75), and 1.8% (n = 8) were positive for atypical pathogens (Bordetella pertussis, n = 3; B. parapertussis, n = 0; Mycoplasma pneumoniae, n = 1; Chlamydophila pneumoniae, n = 3; Legionella pneumophila, n = 1). Among clinical symptoms and signs, only post-tussive vomiting was more frequent in patients with atypical pathogens than those without (P = 0.024). In all, 72.2% of the enrolled patients received antibiotic treatment at their first visits, and beta-lactams (29.4%) and quinolones (20.5%) were the most commonly prescribed agents. In conclusion, our study demonstrates that the incidence of atypical pathogens is low in patients with acute bronchitis, and the rate of antibiotic prescriptions is high.
Subject(s)
Female , Humans , Male , Middle Aged , Anti-Bacterial Agents/therapeutic use , Bordetella parapertussis/genetics , Bordetella pertussis/genetics , Bronchitis/drug therapy , Chlamydophila pneumoniae/genetics , Community-Acquired Infections/microbiology , Hypertension/complications , Legionella pneumophila/genetics , Mycoplasma pneumoniae/genetics , Real-Time Polymerase Chain Reaction , Republic of Korea , Sputum/microbiologyABSTRACT
<p><b>OBJECTIVE</b>To investigate the short-term association between outdoor air pollution and outpatient visits for acute bronchitis, which is a rare subject of research in the mainland of China.</p><p><b>METHODS</b>A time-series analysis was conducted to examine the association of outdoor air pollutants with hospital outpatient visits in Shanghai by using two-year daily data (2010-2011).</p><p><b>RESULTS</b>Outdoor air pollution was found to be associated with an increased risk of outpatient visits for acute bronchitis in Shanghai. The effect estimates of air pollutants varied with the lag structures of the concentrations of the pollutants. For lag06, a 10 μg/m(3) increase in the concentrations of PM10, SO(2), and NO(2) corresponded to 0.94% (95% CI: 0.83%, 1.05%), 11.12% (95% CI: 10.76%, 11.48%), and 4.84% (95% CI: 4.49%, 5.18%) increases in hospital visits for acute bronchitis, respectively. These associations appeared to be stronger in females (P<0.05). Between-age differences were significant for SO(2) (P<0.05), and between-season differences were also significant for SO(2) (P<0.05).</p><p><b>CONCLUSION</b>Our analyses have provided the first evidence that the current air pollution level in China has an effect on acute bronchitis and that the rationale for further limiting air pollution levels in Shanghai should be strengthened.</p>